Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability, PK and PD Characteristics of CMS-D017 Following Single and Multiple Administrations in Healthy Participants

NCT07462780 is registered in ClinicalTrials.gov with Shenzhen Kangzhe Biotechnology Co., Ltd. as lead sponsor.

NCT NCT07462780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07462780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability, PK and PD Characteristics of CMS-D017 Following Single and Multiple Administrations in Healthy Participants
Lead sponsor
Shenzhen Kangzhe Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 5, 2026
Completion date
December 31, 2026
Enrollment
88 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

complement-mediated kidney disease, paroxysmal nocturnal hemoglobinuria, pnh